Object

J&J's MonumenTAL-3 Phase 3 Data for Talvey and Darzalex Faspro Signals Major Shift in Earlier Multiple Myeloma Treatment

J&J's MonumenTAL-3 Phase 3 study, combining bispecific antibody Talvey with Darzalex Faspro for earlier-stage multiple myeloma, has secured a plenary presentation at the 2026 EHA meeting. This signals robust data, positioning J&J to expand its market presence and potentially redefine treatment paradigms for this patient population, impacting competitive strategies and future procurement decisions.